AU2009213138B2 - Methods for the treatment and prevention of age-related retinal dysfunction - Google Patents

Methods for the treatment and prevention of age-related retinal dysfunction Download PDF

Info

Publication number
AU2009213138B2
AU2009213138B2 AU2009213138A AU2009213138A AU2009213138B2 AU 2009213138 B2 AU2009213138 B2 AU 2009213138B2 AU 2009213138 A AU2009213138 A AU 2009213138A AU 2009213138 A AU2009213138 A AU 2009213138A AU 2009213138 B2 AU2009213138 B2 AU 2009213138B2
Authority
AU
Australia
Prior art keywords
cis
formula
retinyl
synthetic retinal
hydroxyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009213138A
Other languages
English (en)
Other versions
AU2009213138A1 (en
Inventor
Tadao Maeda
Krzysztof Palczewski
David Saperstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Publication of AU2009213138A1 publication Critical patent/AU2009213138A1/en
Application granted granted Critical
Publication of AU2009213138B2 publication Critical patent/AU2009213138B2/en
Priority to AU2015200520A priority Critical patent/AU2015200520B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2009213138A 2008-02-11 2009-02-10 Methods for the treatment and prevention of age-related retinal dysfunction Ceased AU2009213138B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2015200520A AU2015200520B2 (en) 2008-02-11 2015-02-04 Methods for the treatment and prevention of age-related retinal dysfunction

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2762508P 2008-02-11 2008-02-11
US61/027,625 2008-02-11
PCT/US2009/000824 WO2009102418A1 (en) 2008-02-11 2009-02-10 Methods for the treatment and prevention of age-related retinal dysfunction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2015200520A Division AU2015200520B2 (en) 2008-02-11 2015-02-04 Methods for the treatment and prevention of age-related retinal dysfunction

Publications (2)

Publication Number Publication Date
AU2009213138A1 AU2009213138A1 (en) 2009-08-20
AU2009213138B2 true AU2009213138B2 (en) 2014-11-06

Family

ID=40521846

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009213138A Ceased AU2009213138B2 (en) 2008-02-11 2009-02-10 Methods for the treatment and prevention of age-related retinal dysfunction

Country Status (14)

Country Link
US (7) US8324270B2 (enExample)
EP (1) EP2252276B1 (enExample)
JP (3) JP6022746B2 (enExample)
KR (2) KR101810381B1 (enExample)
CN (1) CN101969938A (enExample)
AU (1) AU2009213138B2 (enExample)
BR (1) BRPI0908154A2 (enExample)
CA (2) CA3018374A1 (enExample)
IL (2) IL207220B (enExample)
MX (1) MX337656B (enExample)
NZ (3) NZ600498A (enExample)
RU (1) RU2565448C2 (enExample)
WO (1) WO2009102418A1 (enExample)
ZA (1) ZA201005434B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004082622A2 (en) 2003-03-14 2004-09-30 University Of Washington Retinoid replacements and opsin agonists and methods for the use thereof
ES2443194T3 (es) 2004-06-18 2014-02-18 University Of Washington Derivados de retinal y métodos de uso de los mismos para el tratamiento de trastornos visuales
ES2393768T3 (es) 2005-05-26 2012-12-27 Neuron Systems, Inc Derivado de quinolina para el tratamiento de enfermedades retinianas
MX337656B (es) * 2008-02-11 2016-03-14 Univ Washington Metodos para el tratamiento y prevencion de disfuncion retinal relacionada con la edad.
US20120178806A1 (en) 2009-09-15 2012-07-12 Qlt Inc. Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
WO2011072141A1 (en) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
CA2796991A1 (en) * 2010-04-19 2011-10-27 Qlt Inc. Therapeutic regimen and methods for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency
US8846723B2 (en) 2010-07-29 2014-09-30 Eastman Chemical Company Esters of O-substituted hydroxy carboxylic acids and preparations thereof
US8613940B2 (en) 2010-09-03 2013-12-24 Eastman Chemical Company Carbonate derivatives as skin care
US8329938B2 (en) * 2011-02-21 2012-12-11 Eastman Chemical Company Hydroxyalkanoic acid and hydroxyalkanoice acid oligomer esters of retinol
US10226536B2 (en) 2011-11-28 2019-03-12 Case Western Reserve University Polysaccharide therapeutic conjugates
MX389866B (es) * 2012-03-01 2025-03-20 Retinagenix LLC El uso de 9-cis-retinil acetato para mejorar la funcion visual de un sujeto que padece de perdida de la funcion visual originada por una deficiencia retinoide endogena de 11-cis retinal.
CN117045653A (zh) 2013-01-23 2023-11-14 奥尔德拉医疗公司 与毒性醛相关的疾病和治疗
WO2015184453A1 (en) 2014-05-30 2015-12-03 Case Western Reserve University Retinylamine derivitives for treatment of ocular disorders
US11129845B2 (en) 2014-06-18 2021-09-28 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
US10925980B2 (en) 2014-08-04 2021-02-23 Case Western Reserve University Molecular probes and methods of use
US11407786B2 (en) 2015-06-18 2022-08-09 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
JP6947406B2 (ja) 2015-08-21 2021-10-13 アルデイラ セラピューティクス， インコーポレイテッド 重水素化化合物およびその使用
US12060318B2 (en) 2015-10-09 2024-08-13 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
WO2017196881A1 (en) 2016-05-09 2017-11-16 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
AU2018234919A1 (en) 2017-03-16 2019-09-19 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
JP7311162B2 (ja) 2017-10-10 2023-07-19 アルデイラ セラピューティクス， インコーポレイテッド 炎症性障害の処置
CN112714762A (zh) 2018-08-06 2021-04-27 奥尔德拉医疗公司 多晶型化合物及其用途
WO2020223717A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
EP3962894A4 (en) 2019-05-02 2023-01-11 Aldeyra Therapeutics, Inc. POLYMORPHIC COMPOUNDS AND USES THEREOF
US20230034053A1 (en) * 2019-09-25 2023-02-02 The Board Of Trustees Of The Leland Stanford Junior University Metabolic rescue of retinal degeneration
CA3175856A1 (en) 2020-05-13 2021-11-18 Todd Brady Pharmaceutical formulations and uses thereof
WO2021252421A1 (en) * 2020-06-09 2021-12-16 Retinagenix Holdings Llc Methods of treating visual disorders using daily low dosing of a retinoid compound

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029315A1 (en) * 1997-12-10 1999-06-17 Karageozian, Hampar Taurine derivatives usable in the treatment of ophthalmic disorders
WO2006002097A2 (en) * 2004-06-18 2006-01-05 University Of Washington Retinal derivatives and methods for the use thereof for the treatment of visual disorders

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3196076A (en) 1961-12-20 1965-07-20 Schering Corp Anti-depressant 10-(3-dimethylaminopropyl)-3-azaphenothiazine
US3196078A (en) * 1962-01-30 1965-07-20 Ortho Pharma Corp Process for combating retinits pigmentosa
US3517067A (en) 1964-02-11 1970-06-23 Eastman Kodak Co Syntheses of quaternary phosphonium salts
DE2300107C2 (de) 1973-01-03 1982-03-11 Basf Ag, 6700 Ludwigshafen Vitamin A-Säureanilid-4-carbonsäureäthylester, Verfahren zu seiner Herstellung und diesen enthaltende Zubereitungen
DE2456959A1 (de) 1974-12-03 1976-06-16 Basf Ag 4-(e)- und 4-(z)-7-methyl-9-(2,6,6trimethyl-1-cyclohexen-1-yl)-nona-2,4,6,8tetraencarbonsaeure, ihre derivate und diese enthaltende zubereitungen
JPS61275266A (ja) 1985-05-28 1986-12-05 Taisho Pharmaceut Co Ltd レチノイド誘導体
US5310764A (en) 1992-05-08 1994-05-10 Steven Baranowitz Treatment of age related macular degeneration with beta-carotene
JPH06340525A (ja) 1993-06-02 1994-12-13 Lion Corp 安定な低眼刺激性ビタミンａ類可溶化点眼剤
CA2185699A1 (en) 1994-04-04 1995-10-12 William R. Freeman Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure
RU2106843C1 (ru) 1994-06-29 1998-03-20 Красноярская государственная медицинская академия Способ лечения близорукости
JPH08198746A (ja) 1995-01-18 1996-08-06 Lion Corp 可溶化点眼剤
US5837728A (en) 1995-01-27 1998-11-17 Molecular Design International 9-cis retinoic acid esters and amides and uses thereof
US5489611A (en) 1995-02-10 1996-02-06 Warner-Lambert Company Method for lowering plasma levels of lipoprotein (a)
US5620970A (en) 1995-06-05 1997-04-15 Alcon Laboratories, Inc. Topical ophthalmic carbonic anhydrase inhibitor formulations
US5716627A (en) 1996-04-25 1998-02-10 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing fatty acid amides, azoles, and retinol or retinyl ester
EP0908179A1 (en) 1997-08-23 1999-04-14 Werner Bollag Treatment of cell-mediated immune diseases
US6552009B2 (en) 1998-07-16 2003-04-22 Gentrix Llc Compositions and methods of treating abnormal cell proliferation
US6372463B1 (en) 1999-05-06 2002-04-16 The President & Fellows Of Harvard College Mutations in nucleic acid molecules encoding 11-CIS retinol dehydrogenase, the mutated proteins, and uses thereof
WO2000068354A1 (en) 1999-05-07 2000-11-16 Chemlink Laboratories Llc Window cleaner tablet
US6300328B1 (en) 1999-08-06 2001-10-09 Alcon Universal Ltd. Selective inhibitors of adenosine monophosphate deaminase for the treatment of optic nerve and retinal damage
US20020028849A1 (en) 2000-04-18 2002-03-07 Godkin James D. Use of retinol in assisted-reproduction protocols
US6696069B2 (en) 2000-06-30 2004-02-24 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Skin care cosmetic compositions containing phosphates and/or sulfates of branched alcohols and/or ethoxylates thereof
WO2002055540A1 (en) 2001-01-11 2002-07-18 Chebigen Inc. New retinol derivatives, the method of preparations and the uses thereof
CA2435410A1 (en) 2001-01-26 2002-08-01 Steven Baranowitz Systemic formulations containing beta-carotene and derivatives thereof
GB0103998D0 (en) 2001-02-19 2001-04-04 King S College London Method
CA2442670A1 (en) 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
JP2005524626A (ja) 2002-01-18 2005-08-18 タットン テクノロジーズ エルエルシー． 眼疾患を治療するための方法
US20030215413A1 (en) 2002-03-22 2003-11-20 L'oreal Compositions containing stabilized retinoid
US20040097587A1 (en) 2002-03-27 2004-05-20 Arbiser Jack L Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
JP2006512279A (ja) 2002-03-29 2006-04-13 マキシム ファーマシューティカルス，インコーポレイテッド 眼内損傷を治療および予防するためのｒｏｍ生成および放出阻害剤の使用
WO2004082622A2 (en) 2003-03-14 2004-09-30 University Of Washington Retinoid replacements and opsin agonists and methods for the use thereof
JP2007525496A (ja) * 2004-02-17 2007-09-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 黄班変性症を含む眼科疾患の管理
US7566808B2 (en) 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
CA2555261A1 (en) * 2004-02-17 2005-09-01 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
KR20070011379A (ko) 2004-03-17 2007-01-24 라스 미카엘 라르센 시각 사이클 억제에 의한 망막증의 예방
PT1768657E (pt) 2004-06-23 2008-11-25 Sirion Therapeutics Inc Métodos e composições para tratar condições oftálmicas com derivados de retinilo
CA2575265A1 (en) * 2004-08-18 2006-03-30 Sirion Therapeutics, Inc. Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat ophthalmic disorders
WO2006039551A2 (en) 2004-09-30 2006-04-13 The Regents Of The University Of California Local administration of retinoids to treat deficiencies in dark adaptation
EP2687208A1 (en) 2007-09-12 2014-01-22 The Trustees of Columbia University in the City of New York Compositions and Methods for Treating Macular Degeneration
MX337656B (es) 2008-02-11 2016-03-14 Univ Washington Metodos para el tratamiento y prevencion de disfuncion retinal relacionada con la edad.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029315A1 (en) * 1997-12-10 1999-06-17 Karageozian, Hampar Taurine derivatives usable in the treatment of ophthalmic disorders
WO2006002097A2 (en) * 2004-06-18 2006-01-05 University Of Washington Retinal derivatives and methods for the use thereof for the treatment of visual disorders

Also Published As

Publication number Publication date
JP5934304B2 (ja) 2016-06-15
US20130072558A1 (en) 2013-03-21
CA2714530C (en) 2018-09-25
MX337656B (es) 2016-03-14
US8324270B2 (en) 2012-12-04
IL258356A (en) 2018-05-31
US9233091B2 (en) 2016-01-12
JP6022746B2 (ja) 2016-11-09
US20180098955A1 (en) 2018-04-12
CA2714530A1 (en) 2009-08-20
NZ617701A (en) 2015-06-26
US20190133986A1 (en) 2019-05-09
EP2252276B1 (en) 2019-03-27
EP2252276A1 (en) 2010-11-24
JP2016190852A (ja) 2016-11-10
MX2010008847A (es) 2010-11-30
JP2011511789A (ja) 2011-04-14
JP6272943B2 (ja) 2018-01-31
IL207220A0 (en) 2010-12-30
US20130072557A1 (en) 2013-03-21
JP2014221828A (ja) 2014-11-27
RU2565448C2 (ru) 2015-10-20
CN101969938A (zh) 2011-02-09
KR20160092032A (ko) 2016-08-03
US20130072561A1 (en) 2013-03-21
AU2009213138A1 (en) 2009-08-20
RU2010137842A (ru) 2012-03-20
KR20100126358A (ko) 2010-12-01
NZ587376A (en) 2012-06-29
US20160331713A1 (en) 2016-11-17
US20100035986A1 (en) 2010-02-11
ZA201005434B (en) 2011-11-30
BRPI0908154A2 (pt) 2015-08-11
CA3018374A1 (en) 2009-08-20
IL207220B (en) 2018-04-30
US9408821B2 (en) 2016-08-09
WO2009102418A1 (en) 2009-08-20
NZ600498A (en) 2014-01-31
KR101810381B1 (ko) 2017-12-19
US9855239B2 (en) 2018-01-02

Similar Documents

Publication Publication Date Title
AU2009213138B2 (en) Methods for the treatment and prevention of age-related retinal dysfunction
RU2554003C2 (ru) Производные ретиналя и способы их применения для лечения нарушений зрения
US9421175B2 (en) Prevention of retinopathy by inhibition of the visual cycle
CA2796991A1 (en) Therapeutic regimen and methods for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency
US20080275134A1 (en) Methods for Treatment of Retinal Degenerative Disease
AU2015200520B2 (en) Methods for the treatment and prevention of age-related retinal dysfunction
HK1150977B (en) Methods for the treatment and prevention of age-related retinal dysfunction
HK1150977A (en) Methods for the treatment and prevention of age-related retinal dysfunction

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired